Changes in Beneficial Ownership · 4
Septerna, Inc.
SEPNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-11-11
- Issuer
- Septerna, Inc.
- Issuer CIK
- 0001984086
- Trading symbol
- SEPN
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Ezekowitz Alan
- Reporting owner CIK
- 0001780209
- Relationship
- Director
- Address
- C/O SEPTERNA, INC., 250 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-11 | S · Form 4[F1] | 6,939 | D | 46.005[F2] | 110,481 | D |
| Common Stock | 2026-11-11 | S · Form 4[F1] | 13,201 | D | 47.0116[F3] | 97,280 | D |
| Common Stock | 2026-11-11 | S · Form 4[F1] | 22,865 | D | 47.7799[F4] | 74,415 | D |
| Common Stock | 2026-11-11 | S · Form 4[F1] | 31,572 | D | 48.7002[F5] | 42,843 | D |
| Common Stock | 2026-11-11 | S · Form 4[F1] | 4,175 | D | 49.6465[F6] | 38,668 | D |
| Common Stock | 2026-11-11 | S · Form 4[F1] | 2,013 | D | 50.897[F7] | 36,655 | D |
| Common Stock | 2026-11-11 | S · Form 4[F1] | 1,055 | D | 51.9 | 35,600 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on July 13, 2026.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.36 to $46.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F3
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.37 to $47.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F4
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.37 to $48.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F5
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.37 to $49.33. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F6
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.38 to $50.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
- F7
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.47 to $51.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.↩ 1
Signature 1
- Signed
- /s/ Mark A. Wilson, Attorney-in-Fact
- Date
- 2026-11-13
Company context
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com. Septerna intends to use its Investor Relations website and LinkedIn as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Septerna’s Investor Relations website and follow https://www.linkedin.com/company/septernainc on LinkedIn, in addition to following Septerna’s press releases, SEC filings, public conference calls, presentations, and webcasts.